Oak Therapeutics Announces Results of Bioequivalence Study of Company’s Oral Dissolvable Strip for Tuberculosis
Results of In Vivo Study Signifies Completion of another Critical Milestone in Company’s Phase I of NIAID Contract* to Develop ...
Home » Tuberculosis
Results of In Vivo Study Signifies Completion of another Critical Milestone in Company’s Phase I of NIAID Contract* to Develop ...